Loading
AVZO-103 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.
ASCO GU 2026 trial-in-progress abstract TPS908 describes AVZO-103-1001 (BEACON-1), a phase 1/2 study of monotherapy and combinations in advanced urothelial and other solid tumors. The design includes dose escalation followed by expansion. Its rationale and xenograft activity do not constitute patient efficacy results. Trial participation and prior ADC rules depend on the specific cohort.
1.AVZO-103's antibody arm binds TROP2 on the surface of the cancer cell.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AVZO-103" OR ABSTRACT:"AVZO-103") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AVZO-103, not a curated reading list.
Shares Nectin-4, Bispecific ADC, TROP2, Antibody-drug conjugate (ADC).
Shares BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001), Nectin-4, Bispecific ADC, TROP2.
Shares Bispecific ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Nectin-4, TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/